Weill Medical College of Cornell University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Weill Medical College of Cornell University sits in the top decile of US sponsors by registered trial count (#49 of 15,742 sponsors by registered trial count).

701 total trials 127 currently recruiting 387 completed early-phase tilt top decile by trial count

Weill Medical College of Cornell University: 701 sponsored US clinical trials, 127 recruiting.

Weill Medical College of Cornell University sponsors 701 registered US clinical trials on ClinicalTrials.gov, 127 of them currently recruiting, and 387 completed. 89 of these trials are in Phase 3-4 (later-stage) and 197 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 20 trials.

Top-decile sponsor footprint

Weill Medical College of Cornell University ranks in the top decile of sponsors by registered trial count (#49 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 27/100

387 of 515 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

701 total, page 6 of 15

COMPLETED Early Phase 1

Re-treatment 225Ac-J591 for mCRPC

NCT04576871

COMPLETED NA

Giving Information Systematically and Transparently in Lung and GI Cancer Phase 2

NCT04179305

COMPLETED NA

Social Reward and Its Effect on Brain Functions in Psychotherapies for Mid- and Late-Life Depression

NCT04487730

TERMINATED Phase 4

Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)

NCT04406389

COMPLETED NA

Radiofrequency Ablation of Atrial Fibrillation Under Apnea

NCT04170894

COMPLETED NA

Patient-caregiver Communication Intervention for Prognostic Understanding

NCT03833817

COMPLETED Early Phase 1

Carbon-11 Butanol: Whole Body Radiochemical and Radiation Safety

NCT04050800

COMPLETED NA

Reaching and Engaging Depressed Senior Center Clients

NCT04289298

COMPLETED NA

Trauma-focused Psychodynamic Psychotherapy for LGBT Patients With Post-traumatic Stress Disorder

NCT04532996

COMPLETED NA

Comparison of Cannabinoids to Placebo in Management of TMJ Pain and Myofascial Pain in the TMJ Region

NCT04298554

TERMINATED Phase 2

Daratumumab Plus Ibrutinib in Patients With Waldenstrӧm's Macroglobulinemia

NCT03679624

COMPLETED Phase 3

Gabapentin for Post-Operative Pain Control and Narcotic Reduction in Scrotal Surgery

NCT04230980

COMPLETED NA

Trial to Test Effectiveness of Depression Intervention for Mistreated Older Adults

NCT04258579

TERMINATED NA

Use of Cast Iron Pots to Improve Maternal Anemia

NCT02341300

COMPLETED

Assessing Health Related Quality of Life in Hypersensitivity Pneumonitis

NCT04273867

TERMINATED NA

Fetal Genome Profiling Via Trophoblast Cells

NCT03832634

COMPLETED NA

Narrative Medicine and Pediatric Oncology

NCT04489316

TERMINATED NA

A Media Communication Intervention to Increase Engagement in Advance Care Planning Among Cancer Patients

NCT04208009

COMPLETED Phase 4

Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis

NCT03991936

COMPLETED NA

Expansion of Abbreviations and Acronyms for Patients

NCT05297942

COMPLETED Phase 2

Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Dietary Fiber in Patients With Ulcerative Colitis

NCT03998488

COMPLETED NA

Lavender Aromatherapy Spine Procedure Study

NCT04156009

COMPLETED NA

PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer

NCT04220983

COMPLETED

Giving Information Systematically and Transparently in Lung and GI Cancer Phase 1

NCT04158908

COMPLETED

Quantitative Susceptibility Mapping (QSM) to Guide Iron Chelating Therapy

NCT04171635

TERMINATED NA

A Pilot Study of a Strategy and Computer-based Intervention to Enhance Daily Cognitive Functioning After Stroke

NCT04098835

COMPLETED

Trifocal Intraocular Lens (IOL) Aberrometry Outcomes

NCT04196569

TERMINATED Early Phase 1

Feasibility of Administering Clonidine as a Pharmacological Challenge in Imaging Studies

NCT04030572

TERMINATED Phase 2

Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients

NCT04103645

COMPLETED Phase 3

Low Doses of Aspirin in the Prevention of Preeclampsia

NCT04070573

COMPLETED NA

Web-based Family History Tool

NCT04890327

TERMINATED Phase 1

CPX-351+GO in Subjects 55 Years Old, or Older, With AML

NCT03878927

COMPLETED

Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease

NCT03921242

TERMINATED Phase 2

Capecitabine and Temozolomide for Treatment of Recurrent Pituitary Adenomas

NCT03930771

COMPLETED Phase 2

Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

NCT03921021

COMPLETED NA

Pilot Study: The Effects of Medical Music on Anxiety in Patients With ILD

NCT04159584

COMPLETED NA

Reward Function and Therapy for Late-Life Depression

NCT03688139

TERMINATED NA

Developing a Pain Identification and Communication Toolkit

NCT03853291

COMPLETED NA

Study of the Food Order Behavioral Intervention in Prediabetes

NCT03896360

COMPLETED Phase 4

Post-operative Pain Control of Testicular Sperm Extraction Using Liposomal Bupivacaine

NCT03802864

COMPLETED NA

A Personalized Health Behavior System

NCT03538158

TERMINATED Phase 2

Radiotherapy With Immunotherapy for Systemic Effect in Myeloma (RISE-M)

NCT03634800

COMPLETED NA

The CAPTURE Study: Validating a Unique COPD Case Finding Tool in Primary Care (Aim 3)

NCT03583099

COMPLETED

The CAPTURE Study: Validating a Unique COPD Case Finding Tool in Primary Care (Aim 1)

NCT03581227

COMPLETED Phase 4

Effects of Perampanel on Neurophysiology Test Perimeters

NCT03653741

TERMINATED Early Phase 1

A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma

NCT03585725

COMPLETED NA

HCV Seek, Test and Rapid Treatment for Young PWID

NCT03627546

COMPLETED Phase 3

Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles

NCT03223298

COMPLETED NA

MRI-guided Stereotactic Body Radiotherapy (SBRT) With Simultaneous Integrated Boost for Prostate Cancer

NCT03664193

COMPLETED Phase 1

Quantitative Mapping of Substantia Nigra Iron in Parkinson's Disease (Stages I-IV, REM Sleep Behavior Disorder) and Controls

NCT03675282

← Previous Page 6 of 15 Next →

Phase Distribution

PhaseTrial count
Phase 1 86
Phase 2 111
Phase 3 26
Phase 4 63

What is open in the Weill Medical College of Cornell University pipeline

127 recruiting of 701 indexed (18% open); 387 completed (55%).

Phase mix: 89 late (III/IV) vs 197 early (I/II) (early-phase heavy).

Top condition: Prostate Cancer (20 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Weill Medical College of Cornell University: open-pipeline peers nationwide

Peers matched on 701 registered trials and 18% open enrollment, not the therapeutic-area sidebar.

Weill Medical College of Cornell University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0200400600800 5%10%15%20%25% Total trials Recruiting share Weill Medical College of Cornell UniversityIcahn School of Medicine at Mount SinaiSanofiThe Cleveland ClinicUniversity of MiamiChildren's Hospital of PhiladelphiaUniversity of California, BerkeleyBurke Medical Research InstituteGrand Valley State University
Weill Medical College of Cornell University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Weill Medical College of Cornell University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 701 trials (± recruiting share)

Sponsors near 18% open enrollment (± trial volume)

What to do with this Weill Medical College of Cornell University page

701 registered trials is a research-attention snapshot, not an endorsement of Weill Medical College of Cornell University or any single study.

  • 127 of Weill Medical College of Cornell University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Prostate Cancer is the condition Weill Medical College of Cornell University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Weill Medical College of Cornell University pipeline card: 701 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.